Strength in Watson Pharmaceuticals (WPI +3.9%) is attributed to reports of FDA approval of...

|By:, SA News Editor

Strength in Watson Pharmaceuticals (WPI +3.9%) is attributed to reports of FDA approval of Watson partner Amphastar's generic version of Sanofi's (SNY -2.4%) Lovenox blood thinner. Momenta (MNTA -25.9%) and partner Novartis (NVS -1.5%) have sold generic Lovenox exclusively in the U.S. for more than a year.